Sinovac Biotech (SVA) 6.12 $SVA
Sinovac Files 2013 Annual Report on Form 20-F
PR Newswire - Wed Apr 16, 8:15AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16, 2014. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Sinovac Biotech Shares Up 17.4% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Fri Mar 21, 9:23AM CDT
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on March 4th, 2014 at $6.82. In approximately 2 weeks, Sinovac Biotech has returned 17.39% as of today's recent price of $8.00.
Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:39AM CDT
Sinovac Biotech Ltd. was a big mover last session, as its shares rose over 17% on the day.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
Rev Shark: An Odd Market Day
at The Street - Thu Mar 20, 3:49PM CDT
Not bad action, just ... peculiar.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 20, 12:54PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December 31, 2013.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71"
vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM" . The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD" , or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities.
4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
PR Newswire - Wed Jan 29, 6:07AM CST
Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29, 2014. Incidence rates for H7N9 continue to increase in China, with 153 H7N9 Human infectious cases reported in 2013, according to the World Health Organization (WHO). In January 2014, 96 H7N9 cases were reported in China, including 20 fatalities.
The Latest Rubella Pipeline Review
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/bp2w2h/rubella) has announced the addition of the "Rubella - Pipeline Review, H2 2013" report to their offering. 'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Scope - A snapshot of the global therapeutic scenario for Rubella. - A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rubella pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Tables & Figures Introduction Rubella Overview Rubella - Pipeline Products Glance Rubella - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - Cadila Pharmaceuticals Ltd. - Sinovac Biotech Ltd. - Beijing Tiantan Biological Products Co., Ltd. Rubella - Therapeutics Assessment Drug Profiles measles, mumps and rubella vaccine (live) GSK-208136 Live Rubella Vaccine Measles and Rubella Vaccine Vaccine For Live Measles, Mumps and Rubella Rubella Vaccine MMR Varicella Vaccine Rubella - Recent Pipeline Updates Featured News & Press Releases For more information visit http://www.researchandmarkets.com/research/bp2w2h/rubella
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Shares of SVA Up 109.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jan 06, 4:31PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 13 months, Sinovac Biotech has returned 109.30% as of today's recent price of $6.30.
Sinovac Biotech Shares Up 88.7% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Wed Dec 11, 9:35AM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 12 months, Sinovac Biotech has returned 88.70% as of today's recent price of $5.68.
Sinovac Files 2013 Annual Report on Form 20-F
PR Newswire - Wed Apr 16, 8:15AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China that focuses on the research, development, manufacturing and commercialization of vaccines, announced today that it has filed its 2013 Annual Report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2013 on April 16, 2014. The Annual Report on Form 20-F is now available on the Company's website under SEC Filing in the Investor Relations section.
Concise Analysis of the International Human Vaccine Industry
M2 - Tue Mar 25, 5:16AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hfnkh2/china_human) has announced the addition of the "Concise Analysis of the International Human Vaccine Industry" report to their offering. In the wake of China's economic growth and enhanced disease prevention awareness, Chinese human vaccine market has been expanding. In 2012, Chinese human vaccine market valued RMB10.5 billion with the lot release quantity of roughly 773 million person-portions. Restricted by China's national conditions and policies, EPI vaccines still prevail in China and Chinese EPI vaccine market is almost monopolized by state-run enterprises represented by CNBG Tiantan Biological, Biological Products Institutes in Changchun, Chengdu, Wuhan, Shanghai and Lanzhou, and Institute of Medical Biology of Chinese Academy of Medical Sciences in Kunming. In 2012, state-owned enterprises seized 81.5% of the vaccine lot release quantity in Chinese EPI vaccine market. However, along with the gradual relaxed access to the vaccine market, private companies have sprung up in the Extra EPI vaccine market and acquired more market share. Meanwhile, foreign counterparts occupy considerable market share by virtue of their technological and product advantages. In 2012, private and foreign-funded enterprises occupied 49.9% and 22.1% (by lot release quantity) of Chinese Extra EPI vaccine market respectively. As for human rabies vaccine and varicella vaccine markets, they mastered more than 85% of each. Key Topics Covered: 1. Overview of Vaccine Industry 2. Overview of China Human Vaccine Industry 3. Human Vaccine Market Segments in China 4. Human Vaccine Import and Export in China 5. Major Human Vaccine Producers in China Companies Mentioned: - Beijing Tiantan Biological Products Co., Ltd. - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd. - Dalian Hissen Bio-Pharm Co., Ltd. - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd. - Sinovac Biotech Ltd. - Yunnan Walvax Biotechnology Co., Ltd. - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. For more information visit http://www.researchandmarkets.com/research/hf...hina_human
Pre-Market Analysis on Top Gainers -- Research on ZIOPHARM, Centrais Eletricas Brasileiras, Catalyst Pharma Partners and Sinovac Biotech
PR Newswire - Fri Mar 21, 4:18PM CDT
The US markets saw a positive sentiment on Thursday, March 20, 2014, with the NASDAQ Composite closing at 4,319.29, up 0.27%, the Dow Jones Industrial Average ending the session at 16,331.05, up 0.67% and the S&P 500 edging 0.60% higher to finish the trading session at 1,872.01. During the session, gains in the Information Technology, Financials, and Telecommunication Services sectors positively impacted the broader market. A number of stocks saw large movements, including ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Centrais Eletricas Brasileiras S.A. (NYSE: EBR), Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX) and Sinovac Biotech Ltd (NASDAQ: SVA). Free technical research on ZIOP, EBR, CPRX and SVA can be downloaded upon signing up at:
Sinovac Biotech Shares Up 17.4% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Fri Mar 21, 9:23AM CDT
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on March 4th, 2014 at $6.82. In approximately 2 weeks, Sinovac Biotech has returned 17.39% as of today's recent price of $8.00.
Sinovac Biotech (SVA) Soars: Stock Rises 17.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 8:39AM CDT
Sinovac Biotech Ltd. was a big mover last session, as its shares rose over 17% on the day.
Nasdaq stocks posting largest volume increases
AP - Thu Mar 20, 5:05PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Why Sinovac Biotech, Burlington Stores, and ZIOPHARM Oncology Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 20, 4:15PM CDT
Mixed, but stabilizing, economic data was the name of the game today that helped push the broad-based S&P 500 higher, practically erasing almost all of yesterday's losses. As per the norm, we got initial weekly jobless claims data today,...
Rev Shark: An Odd Market Day
at The Street - Thu Mar 20, 3:49PM CDT
Not bad action, just ... peculiar.
Nasdaq stocks posting largest percentage increases
AP - Thu Mar 20, 12:54PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Sinovac Reports Unaudited Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Wed Mar 19, 5:00PM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited fourth quarter and full year financial results for the period ended December 31, 2013.
Sinovac to Host Conference Call to Report Fourth Quarter and Full Year 2013 Unaudited Financial Results
PR Newswire - Wed Mar 12, 5:00AM CDT
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, today announced that it will release its unaudited financial results for the fourth quarter and whole year ended December 31, 2013, after market closes on Wednesday, March 19, 2014 EDT. The Company will host a conference call prior to the market opening on Thursday, March 20, 2014, at 8:00 a.m. EDT (Thursday, March 20, 2014 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments.
Sinovac's EV71 Vaccine Phase III Clinical Trial Results Published in New England Journal of Medicine
PR Newswire - Wed Feb 26, 4:01PM CST
Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that Phase III clinical trial results for its proprietary Enterovirus 71 ("EV71"
vaccine have been published online in the February 27th issue of The New England Journal of Medicine ("NEJM" . The clinical results showed the efficacy of the vaccine against EV71-associated hand, foot and mouth disease ("HFMD" , or herpangina, was 94.8% among infants and young children and an anti-EV71 neutralizing antibody titer of 1:16 was associated with protection against EV71 associated HFMD or herpangina. As outlined in the NEJM article, Sinovac's vaccine also demonstrated a 100% efficacy rate against EV71-associated hospitalization and against HFMD with neurologic complications, the main cause of fatalities. 4 Stocks Under $10 in Breakout Territory
at The Street - Wed Feb 12, 5:30AM CST
These under-$10 stocks are within range of triggering breakout trades.
Sinovac Biotech Ltd submits CTA with the CFDA to commence human clinical trials of its H7N9 avian influenza vaccine
M2 - Thu Jan 30, 3:10AM CST
Biopharmaceutical company Sinovac Biotech Ltd (NasdaqGS:SVA) reported on Wednesday the submission of a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to begin human clinical trials of its vaccine against Avian influenza A(H7N9) virus.
Sinovac Files Clinical Trial Application with CFDA for its Proprietary Vaccine against Avian Influenza A(H7N9) Virus
PR Newswire - Wed Jan 29, 6:07AM CST
Sinovac Biotech Ltd. (Nasdaq:SVA), a leading provider of biopharmaceutical products in China, announced today that it has submitted a Clinical Trial Application(CTA) with the China Food and Drug Administration (CFDA) to commence human clinical trials for its vaccine against Avian influenza A(H7N9) virus. The CTA was officially accepted by CFDA on January 29, 2014. Incidence rates for H7N9 continue to increase in China, with 153 H7N9 Human infectious cases reported in 2013, according to the World Health Organization (WHO). In January 2014, 96 H7N9 cases were reported in China, including 20 fatalities.
The Latest Rubella Pipeline Review
M2 - Mon Jan 27, 10:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/bp2w2h/rubella) has announced the addition of the "Rubella - Pipeline Review, H2 2013" report to their offering. 'Rubella - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rubella, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rubella. Scope - A snapshot of the global therapeutic scenario for Rubella. - A review of the Rubella products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Rubella pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Tables & Figures Introduction Rubella Overview Rubella - Pipeline Products Glance Rubella - Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Zydus Cadila Healthcare Limited - Cadila Pharmaceuticals Ltd. - Sinovac Biotech Ltd. - Beijing Tiantan Biological Products Co., Ltd. Rubella - Therapeutics Assessment Drug Profiles measles, mumps and rubella vaccine (live) GSK-208136 Live Rubella Vaccine Measles and Rubella Vaccine Vaccine For Live Measles, Mumps and Rubella Rubella Vaccine MMR Varicella Vaccine Rubella - Recent Pipeline Updates Featured News & Press Releases For more information visit http://www.researchandmarkets.com/research/bp2w2h/rubella
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
Shares of SVA Up 109.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Jan 06, 4:31PM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 13 months, Sinovac Biotech has returned 109.30% as of today's recent price of $6.30.
Sinovac Biotech Shares Up 88.7% Since SmarTrend's Buy Recommendation (SVA)
Comtex SmarTrend(R) - Wed Dec 11, 9:35AM CST
SmarTrend identified an Uptrend for Sinovac Biotech (AMEX:SVA) on December 21st, 2012 at $3.01. In approximately 12 months, Sinovac Biotech has returned 88.70% as of today's recent price of $5.68.
